Does Calibrate Prescribe Metformin?

What Calibrate's Program Actually Prescribes

Calibrate markets itself as a "metabolic health" program, and its clinical model is organized around GLP-1 receptor agonists (GLP-1 RAs) as the cornerstone medication. Semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza) are the drugs most commonly associated with the program. Calibrate physicians work within a telehealth framework and are licensed in the states they practice, so the actual prescribing decision always rests with the treating clinician.

Metformin is not listed as the default or primary drug in Calibrate's published program documentation. It may appear as an add-on for patients with prediabetes, type 2 diabetes, or polycystic ovary syndrome (PCOS), but only when the prescribing physician determines it is clinically appropriate.

Why GLP-1 Agonists, Not Metformin

GLP-1 receptor agonists produce substantially greater weight reduction than metformin in head-to-head comparisons. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced a mean body-weight reduction of 14.9% at 68 weeks versus 2.4% for placebo (P<0.001) [1]. Metformin, by contrast, produced roughly 2 to 3 kg of weight loss over 12 to 24 months in the Diabetes Prevention Program (DPP, N=3,234) [2]. The gap in efficacy explains why a commercial weight-loss platform defaults to GLP-1 agents.

How Calibrate Physicians Decide on Medications

Every Calibrate member is evaluated by a physician who reviews their intake questionnaire, labs, and health history before issuing any prescription. The clinical criteria Calibrate uses internally have not been published in a peer-reviewed journal, but the company states that its physicians follow evidence-based guidelines. The American Diabetes Association's 2024 Standards of Care recommend metformin as a first-line agent for type 2 diabetes management and acknowledge its modest weight-lowering effect, while placing GLP-1 RAs in a superior tier for weight-centric outcomes [3].

If a member has contraindications to GLP-1 RAs, such as a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, the FDA labeling for semaglutide carries a boxed warning and the physician would need to consider alternatives. Metformin could reasonably appear in that scenario [4].

Metformin: What It Is and What It Does

Metformin (biguanide class) has been in clinical use since the 1950s and received FDA approval for type 2 diabetes in 1994 [5]. Its primary mechanism is suppression of hepatic glucose production via inhibition of complex I of the mitochondrial respiratory chain, reducing fasting plasma glucose without stimulating insulin secretion, which means hypoglycemia risk is minimal when used as monotherapy.

Weight Effects of Metformin

Weight loss with metformin is real but modest. In the DPP trial (N=3,234), participants randomized to metformin 850 mg twice daily lost an average of 2.06 kg at one year compared with 0.02 kg in the placebo group [2]. The DPP Outcomes Study showed that this modest weight reduction persisted at 15-year follow-up, though the magnitude remained far below what GLP-1 RAs achieve.

Metformin also appears to reduce appetite through mechanisms that may involve GDF-15 signaling and mild nausea, though these pathways are still being characterized in the literature [6].

Longevity Signals for Metformin

Outside of diabetes and weight, metformin has attracted attention as a potential longevity agent. Preclinical data show activation of AMPK and downstream effects on mTOR that are associated with extended lifespan in animal models. The TAME (Targeting Aging with Metformin) trial, a multi-center, placebo-controlled study targeting N=3,000 adults aged 65 to 79 without diabetes, is currently enrolling and aims to determine whether metformin delays the onset of age-related disease clusters [7]. Results are not yet available.

The American Federation for Aging Research describes the TAME trial as "the first trial designed specifically to test a drug's ability to delay aging." Observational data from a 2019 cohort study (N=41,204) published in Diabetes Care suggested that metformin users with type 2 diabetes had lower all-cause mortality compared with matched non-diabetic controls not on metformin, though confounding in observational designs limits causal inference [8].

GLP-1 Receptor Agonists: The Clinical Case Calibrate Builds On

Efficacy Data

Calibrate's program rests on a well-documented evidence base. The STEP program tested semaglutide 2.4 mg weekly across multiple populations.

• STEP-1 (N=1,961, adults with obesity, no diabetes): 14.9% mean weight loss at 68 weeks [1].
• STEP-3 (N=611, intensive behavioral therapy added): 16.0% mean weight loss at 68 weeks [9].
• STEP-5 (N=304, 104-week extension): 15.2% mean weight loss at 2 years [10].

Liraglutide 3.0 mg (Saxenda) showed 8.0% mean weight loss at 56 weeks in the SCALE Obesity and Prediabetes trial (N=3,731) [11]. Calibrate has referenced liraglutide as one of its prescribable agents, particularly when Wegovy supply constraints affect availability.

Cardiovascular Outcomes

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo in adults with obesity and established cardiovascular disease but without diabetes (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) [12]. This cardiovascular benefit goes well beyond anything metformin has shown in non-diabetic populations.

Side-Effect Profile

GLP-1 RAs carry a meaningful gastrointestinal side-effect burden. Nausea affects roughly 44% of semaglutide users in trials, and approximately 4.5% discontinue due to GI events [1]. Pancreatitis is rare but included in FDA labeling as a risk requiring clinical monitoring [4]. Metformin's main side effects are also GI (diarrhea, nausea), affecting up to 30% of users, but these typically resolve with dose titration and are rarely serious [5].

When Calibrate Might Include Metformin

The following framework describes the clinical scenarios in which a Calibrate physician would most plausibly consider metformin alongside or instead of a GLP-1 RA. This is based on published clinical guidelines and the known structure of Calibrate's intake and prescribing model, reviewed by the HealthRX medical team.

Scenario 1: GLP-1 RA contraindication. A patient with a personal history of medullary thyroid carcinoma cannot receive semaglutide or liraglutide per FDA labeling. Metformin becomes one of the few metabolic medications the physician can offer within a telehealth framework.

Scenario 2: Insurance denial for GLP-1 RA. GLP-1 RAs can cost $900 to $1,400 per month without coverage. If a prior-authorization appeal fails, the physician may bridge with metformin while the insurance process continues.

Scenario 3: Prediabetes or PCOS. The ADA 2024 Standards of Care explicitly recommend metformin for prediabetes prevention, particularly in individuals with BMI 35 kg/m or higher, age <60, or prior gestational diabetes [3]. Calibrate's intake captures A1C and fasting glucose, and a physician seeing A1C of 5.7 to 6.4% may add metformin even while also prescribing a GLP-1 RA.

Scenario 4: Dose titration bridge. During the early weeks of GLP-1 dose titration, metabolic benefits are modest. Some clinicians add metformin to accelerate early glucose improvement in patients with type 2 diabetes, consistent with combination therapy evidence.

Scenario 5: Longevity-focused patient request. A patient without diabetes or obesity who wants metformin for potential longevity reasons falls outside Calibrate's target population (Calibrate requires BMI 30+, or BMI 27+ with a comorbidity). Such a patient would likely not qualify for the program at all, making this scenario uncommon for Calibrate's membership.

Calibrate vs. Other Telehealth Providers on Metformin

Not all telehealth metabolic health companies handle metformin the same way. Understanding the differences helps patients choose the right platform.

Providers That Prescribe Metformin Primarily

Some telehealth platforms, including certain online pharmacies with prescribing services, will prescribe metformin for weight management or longevity purposes off-label after a brief async consultation. The off-label use for obesity or anti-aging is legal but not FDA-approved, and the evidentiary bar for these indications is much lower than for GLP-1 RAs.

Providers That Focus on GLP-1 RAs

Calibrate, Ro Body, and Noom Med each center their programs on GLP-1 RA prescribing. These platforms differ in cost structure, coaching intensity, and insurance navigation support, but all treat GLP-1 RAs as the primary pharmacological tool.

Hybrid Approaches

Some clinicians practicing functional or longevity medicine combine low-dose metformin (500 mg daily) with a GLP-1 RA and lifestyle intervention. The published combination data are limited but not discouraging. A 2021 RCT (N=120) published in Diabetes, Obesity and Metabolism found that adding metformin to liraglutide 1.8 mg modestly improved HbA1c compared to liraglutide alone at 26 weeks, though the weight difference was not statistically significant [13].

How to Get Metformin Prescribed Through Telehealth

If metformin is your primary goal and you do not have type 2 diabetes, here is a direct clinical path.

Step 1: Get Baseline Labs

A prescribing physician needs at minimum: fasting plasma glucose, HbA1c, and a basic metabolic panel (BMP) to assess renal function. Metformin is contraindicated when eGFR drops below 30 mL/min/1.73 m² and requires dose adjustment at eGFR <45 mL/min/1.73 m² per FDA labeling [5]. Order these before your first telehealth visit to avoid delays.

Step 2: Know Your Indication

Physicians are most comfortable prescribing metformin when a clear indication exists: type 2 diabetes (FDA-approved), prediabetes (ADA-recommended, off-label), PCOS (common off-label use supported by ACOG guidance [14]), or gestational diabetes history. If your indication is longevity without any glucose abnormality, expect more discussion and possibly a refusal, as the evidence for this indication is preliminary.

Step 3: Choose the Right Platform

Calibrate is not the most direct path to a standalone metformin prescription. A primary care physician, endocrinologist, or a telehealth platform specializing in metabolic or diabetes care will likely be more efficient if metformin is your sole goal. HealthRX physicians can evaluate whether metformin, a GLP-1 RA, or a combination protocol fits your labs and health history.

Step 4: Discuss Extended-Release vs. Immediate-Release

Metformin immediate-release (IR) causes GI side effects in up to 30% of users. Extended-release metformin (ER/XR) reduces GI burden significantly. A 2019 meta-analysis of 17 RCTs (N=2,988) in the British Journal of Clinical Pharmacology confirmed that ER formulations produced significantly lower rates of diarrhea and nausea compared to IR [15]. Ask specifically for ER if GI tolerance has been a concern in the past.

Safety Considerations Every Patient Should Know

Lactic Acidosis

Metformin carries a boxed FDA warning for lactic acidosis. The actual incidence is roughly 3 cases per 100,000 patient-years, making it rare but not negligible [5]. Risk is concentrated in patients with renal impairment, hepatic insufficiency, or conditions causing tissue hypoxia.

Vitamin B12 Depletion

Long-term metformin use reduces vitamin B12 absorption in the terminal ileum. The DPP Outcomes Study showed that metformin users had a 13% lower mean B12 level than placebo users after 5 years (P<0.001) [2]. The ADA 2024 Standards recommend periodic B12 monitoring in long-term metformin users, particularly those with peripheral neuropathy [3].

Drug Interactions

Metformin interacts with iodinated contrast agents (hold 48 hours before and after contrast imaging) and with alcohol (increased lactic acidosis risk). The prescribing physician should review the full medication list, including over-the-counter supplements.

GLP-1 RA Safety Signals

For completeness: GLP-1 RAs carry FDA warnings for thyroid C-cell tumors (based on rodent data), pancreatitis, and, for semaglutide specifically, a possible association with non-arteritic anterior ischemic optic neuropathy being evaluated in post-marketing surveillance [4]. The clinical significance of the latter signal is still under investigation.

What to Ask Your Calibrate Physician

Patients entering Calibrate's program who want to discuss metformin should prepare specific questions for their physician visit.

1. "My A1C is 5.8%. Do your clinical guidelines recommend metformin alongside the GLP-1 RA you are planning to prescribe?"
2. "If my insurance denies the GLP-1 prior authorization, would metformin be an appropriate bridge medication while I appeal?"
3. "I have PCOS. Is metformin part of your standard protocol for patients with my diagnosis?"
4. "Can you order a baseline B12 level before starting metformin so we have a reference point for future monitoring?"

Direct, specific questions help the physician address your situation rather than defaulting to the program's standard script.

Key Differences at a Glance: Metformin vs. GLP-1 RAs

| Feature | Metformin | GLP-1 RAs (semaglutide) | |---|---|---| | FDA approval for weight loss | No | Yes (Wegovy) | | Mean weight loss | 2 to 3 kg / 12 to 24 months | 14.9% / 68 weeks | | Route | Oral tablet | Weekly subcutaneous injection | | Cost (generic) | $4, $10/month | $900, $1,400/month without coverage | | Cardiovascular outcome data | UKPDS (diabetes only) | SELECT (20% MACE reduction) | | Longevity trial | TAME (ongoing) | No dedicated aging trial | | Main side effects | GI, B12 depletion | GI, thyroid warning | | Calibrate default? | No | Yes |